Shorts
1:32
MDS 2025: Environmental Exposures and PD
5 months ago
by
Web Ross, MD(+1 more)
0:53
MDS 2025: Novel Therapeutics and Biomarkers for PD
5 months ago
by
Veronica Santini, MD, MA(+1 more)
0:38
MDS 2025: PD and the Gut Microbiome
5 months ago
by
Samia Ben Sassi, MD(+1 more)
1:49
MDS 2025: Parkinson Disease and Brain Organization
5 months ago
by
A. Jon Stoessl, CM, MD(+1 more)
0:53
MDS 2025: Exercise and Diet's Impact on Parkinson Disease
5 months ago
by
Jonas Hannestad, MD, PhD(+1 more)
1:21
Migraine Care Needs of the LGBTQIA+ Patient Population
5 months ago
by
Anna Pace, MD(+1 more)
1:16
Impact of Speech and Physical Therapy in Parkinson Disease
5 months ago
by
Cynthia Fox, PhD, CCC-SLP(+1 more)
1:33
Biomarkers to Guide Remyelination Strategies in MS
5 months ago
by
Ahmed Abdelhak, MD(+1 more)
1:07
Early Identification of Atypical Parkinsonian Syndromes
6 months ago
by
David Shprecher, DO, MSci, FAAN(+1 more)
1:28
Subjective Cognitive Complaints During the Interictal Period in Migraine
6 months ago
by
Laura Sebrow, PhD(+1 more)
1:10
Consensus Definitions for Refractory and Resistant Migraine
6 months ago
by
Jennifer Robblee, MD(+1 more)
1:10
The Future of Migraine Treatment
6 months ago
by
Patricia Pozo-Rosich, MD, PhD(+1 more)
1:10
Understanding Adolescent Migraine Suffering
6 months ago
by
Patricia Pozo-Rosich, MD, PhD(+1 more)
0:30
Overviewing New Gene Therapy Guidelines w/ Dr. Byrne
6 months ago
by
Marco Meglio(+1 more)
1:00
Multidisciplinary Care for Gene Therapy Use in DMD
6 months ago
by
Marco Meglio(+1 more)
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Breaking Down the 2026 Acute Ischemic Stroke Guidelines
2
Fenebrutinib Achieves Primary End Point in Phase 3 Head-to-Head Trial vs Teriflunomide in Relapsing MS
3
Real-World Effectiveness of Eptinezumab After CGRP Preventive Failure: Amaal Starling, MD, FAHS, FAAN
4
Real-World INFUSE Data Show IV Eptinezumab Improves Outcomes After CGRP Failure
5